FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134758619> ?p ?o ?g. }

• W2134758619 abstract "Anti-signal recognition particle (SRP) antibodies are used as serological markers of necrotizing myopathy, which is characterized by many necrotic and regenerative muscle fibers without or with minimal inflammatory cell infiltration. The clinical spectrum associated with anti-SRP antibodies seems to be broad.To describe the clinical characteristics, autoantibodies status, and neurological outcome associated with anti-SRP antibody.We studied clinical and laboratory findings of 100 patients with inflammatory myopathy and anti-SRP antibodies. Anti-SRP antibodies in serum were detected by the presence of 7S RNA using RNA immunoprecipitation. In addition, enzyme-linked immunosorbent assays (ELISAs) using a 54-kD protein of SRP (SRP54) and 3-hydroxyl-3-methylglutatyl-coenzyme A reductase (HMGCR) were also conducted.The mean onset age of the 61 female and 39 male patients was 51 years (range 4-82 years); duration ≥ 12 months before diagnosis was seen in 23 cases. All patients presented limbs weakness; 63 had severe weakness, 70 neck weakness, 41 dysphagia, and 66 muscle atrophy. Extramuscular symptoms and associated disorders were infrequent. Creatine kinase levels were mostly more than 1000 IU/L. Histological diagnosis showed 84 patients had necrotizing myopathy, and apparent cell infiltration was observed in 16 patients. Anti-SRP54 antibodies were undetectable in 18 serum samples with autoantibodies to 7S RNA. Anti-HMGCR antibodies were positive in 3 patients without the statin treatment, however, were negative in 5 patients with statin-exposure at disease onset. All but 3 patients were treated by corticosteroids and 62 (77 %) of these 81 patients required additional immunotherapy. After 2-years treatment, 22 (27 %) of these 81 patients had poor neurological outcomes with modified Rankin scale scores of 3-5. Multivariate analysis revealed that pediatric disease onset was associated with the poor outcomes.Anti-SRP antibodies are associated with different clinical courses and histological presentations." @default.
• W2134758619 created "2016-06-24" @default.
• W2134758619 creator A5008182946 @default.
• W2134758619 creator A5022478812 @default.
• W2134758619 creator A5024263998 @default.
• W2134758619 creator A5037587567 @default.
• W2134758619 creator A5061562486 @default.
• W2134758619 creator A5063738564 @default.
• W2134758619 creator A5069310256 @default.
• W2134758619 creator A5069628033 @default.
• W2134758619 creator A5075788011 @default.
• W2134758619 date "2015-05-13" @default.
• W2134758619 modified "2023-10-18" @default.
• W2134758619 title "Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients" @default.
• W2134758619 cites W1505615828 @default.
• W2134758619 cites W1964834913 @default.
• W2134758619 cites W1971481820 @default.
• W2134758619 cites W1973552403 @default.
• W2134758619 cites W1982008427 @default.
• W2134758619 cites W2020615609 @default.
• W2134758619 cites W2024761668 @default.
• W2134758619 cites W2025942670 @default.
• W2134758619 cites W2028983972 @default.
• W2134758619 cites W2031973282 @default.
• W2134758619 cites W2050719786 @default.
• W2134758619 cites W2051103305 @default.
• W2134758619 cites W2061067602 @default.
• W2134758619 cites W2079665036 @default.
• W2134758619 cites W2109532342 @default.
• W2134758619 cites W2114356729 @default.
• W2134758619 cites W2128695214 @default.
• W2134758619 cites W2151179012 @default.
• W2134758619 cites W2155871238 @default.
• W2134758619 cites W2167782836 @default.
• W2134758619 cites W2197599744 @default.
• W2134758619 doi "https://doi.org/10.1186/s13023-015-0277-y" @default.
• W2134758619 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4440264" @default.
• W2134758619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25963141" @default.
• W2134758619 hasPublicationYear "2015" @default.
• W2134758619 type Work @default.
• W2134758619 sameAs 2134758619 @default.
• W2134758619 citedByCount "149" @default.
• W2134758619 countsByYear W21347586192015 @default.
• W2134758619 countsByYear W21347586192016 @default.
• W2134758619 countsByYear W21347586192017 @default.
• W2134758619 countsByYear W21347586192018 @default.
• W2134758619 countsByYear W21347586192019 @default.
• W2134758619 countsByYear W21347586192020 @default.
• W2134758619 countsByYear W21347586192021 @default.
• W2134758619 countsByYear W21347586192022 @default.
• W2134758619 countsByYear W21347586192023 @default.
• W2134758619 crossrefType "journal-article" @default.
• W2134758619 hasAuthorship W2134758619A5008182946 @default.
• W2134758619 hasAuthorship W2134758619A5022478812 @default.
• W2134758619 hasAuthorship W2134758619A5024263998 @default.
• W2134758619 hasAuthorship W2134758619A5037587567 @default.
• W2134758619 hasAuthorship W2134758619A5061562486 @default.
• W2134758619 hasAuthorship W2134758619A5063738564 @default.
• W2134758619 hasAuthorship W2134758619A5069310256 @default.
• W2134758619 hasAuthorship W2134758619A5069628033 @default.
• W2134758619 hasAuthorship W2134758619A5075788011 @default.
• W2134758619 hasBestOaLocation W21347586191 @default.
• W2134758619 hasConcept C126322002 @default.
• W2134758619 hasConcept C141071460 @default.
• W2134758619 hasConcept C142724271 @default.
• W2134758619 hasConcept C159654299 @default.
• W2134758619 hasConcept C163764329 @default.
• W2134758619 hasConcept C203014093 @default.
• W2134758619 hasConcept C2776418732 @default.
• W2134758619 hasConcept C2777300911 @default.
• W2134758619 hasConcept C2780181341 @default.
• W2134758619 hasConcept C2780247198 @default.
• W2134758619 hasConcept C36880943 @default.
• W2134758619 hasConcept C71924100 @default.
• W2134758619 hasConcept C90924648 @default.
• W2134758619 hasConceptScore W2134758619C126322002 @default.
• W2134758619 hasConceptScore W2134758619C141071460 @default.
• W2134758619 hasConceptScore W2134758619C142724271 @default.
• W2134758619 hasConceptScore W2134758619C159654299 @default.
• W2134758619 hasConceptScore W2134758619C163764329 @default.
• W2134758619 hasConceptScore W2134758619C203014093 @default.
• W2134758619 hasConceptScore W2134758619C2776418732 @default.
• W2134758619 hasConceptScore W2134758619C2777300911 @default.
• W2134758619 hasConceptScore W2134758619C2780181341 @default.
• W2134758619 hasConceptScore W2134758619C2780247198 @default.
• W2134758619 hasConceptScore W2134758619C36880943 @default.
• W2134758619 hasConceptScore W2134758619C71924100 @default.
• W2134758619 hasConceptScore W2134758619C90924648 @default.
• W2134758619 hasIssue "1" @default.
• W2134758619 hasLocation W21347586191 @default.
• W2134758619 hasLocation W21347586192 @default.
• W2134758619 hasLocation W21347586193 @default.
• W2134758619 hasLocation W21347586194 @default.
• W2134758619 hasOpenAccess W2134758619 @default.
• W2134758619 hasPrimaryLocation W21347586191 @default.
• W2134758619 hasRelatedWork W2016770909 @default.
• W2134758619 hasRelatedWork W2047785253 @default.
• W2134758619 hasRelatedWork W2121785953 @default.
• W2134758619 hasRelatedWork W2230622981 @default.
• W2134758619 hasRelatedWork W2327481983 @default.

• next